Evaluation of the effectiveness of Cyproheptadine on paroxysmal short-time headache in childre

Phase 3

Conditions: Episodic Paroxysmal hemicrania.
Episodic paroxysmal hemicrania
G44.03

Registration Number: IRCT20190208042654N5

Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 20

Inclusion Criteria

Children with 2 to 15 years of age
Children with episodic paroxysmal hemicrania referred to neurology clinic whose disease has been definitively diagnosed according to the ICHD criteria.
Number of attacks of equal or more than once a week

Exclusion Criteria

Patients' unwillingness to cooperate during the study
Severe and uncontrollable side effects of cyproheptadine
If, based on possible laboratory or imaging findings, a diagnosis other than episodic paroxysmal hemicrania is made during the study
Epilepsy or epileptic headaches
Existence of structural anomalies in MRI imaging
History of allergies to similar drugs
Inability to record data on the number, duration, and severity of headaches
Taking a prophylactic drug other than Cyproheptadine
Severe psychiatric problems such as depression or ADHD

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency, duration, and severity of headache attacks and drug side effects. Timepoint: before intervention and each month after intervention. Method of measurement: Checklist includes measuring the number of attacks per week, the duration of attacks in form of minutes and its severity according to the VAS criteria and the occurrence of known side effects.

Secondary Outcome Measures